Evox Therapeutics Ltd, an Oxford-based biotechnology company, has named Dr David Lowe as its new vice president of research, it was reported on Tuesday.

In the new role, Lowe will be managing the research group with the aim of advancing the company's pipeline and continuing the development of its proprietary exosome platform.

Dr Lowe has more than 20 years of biotech and large pharma R&D experience in advancing protein and antibody-based therapeutics and exploring novel therapeutic modalities such as gene therapy, mRNA therapeutics and exosomes. He has spent more than 12 years at AstraZeneca, most recently as senior director of Biologics Engineering. He has spent around 10 years at Cambridge Antibody Technology. He was also a principal investigator on a USD17m grant from the Defense Advanced Research Projects Agency.